

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/461,829	12/15/1999	ROBERT-JAN ENZERINK	265280-64723	4338
75	90 01/13/2003			
SUSANNE M. HOPKINS, ESQ.			EXAMINER	
LIFENET 7101 BLOOMSBURY LANE SPOTSYLVANIA, VA 22553			PELLEGRINO, BRIAN E	
			ART UNIT	PAPER NUMBER
			3738	<u> </u>
			DATE MAILED: 01/13/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

-	<u> </u>	\mathcal{S}
,	Application No.	Applicant(s)
Advisory Action	09/461,829	ENZERINK ET AL.
	Examiner	Art Unit
	Brian E Pellegrino	3738
The MAILING DATE of this communication appe	ears on the cover sheet with the o	correspondence address
THE REPLY FILED 02 January 2003 FAILS TO PLACE Therefore, further action by the applicant is required to avignal rejection under 37 CFR 1.113 may only be either: (1) condition for allowance; (2) a timely filed Notice of Appeal Examination (RCE) in compliance with 37 CFR 1.114.	THIS APPLICATION IN CONDI	TION FOR ALLOWANCE. ation. A proper reply to a
PERIOD FOR RE	PLY [check either a) or b)]	
 a)	dvisory Action, or (2) the date set forth ater than SIX MONTHS from the mailing FILED WITHIN TWO MONTHS OF TH	g date of the final rejection. IE FINAL REJECTION. See MPEP
Extensions of time may be obtained under 37 CFR 1.136(a). The fee have been filed is the date for purposes of determining the period of fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of ti (2) as set forth in (b) above, if checked. Any reply received by the Offic timely filed, may reduce any earned patent term adjustment. See 37 CI	rextension and the corresponding amore the shortened statutory period for reply on the safter the mail FR 1.704(b).	unt of the fee. The appropriate extension originally set in the final Office action; or ing date of the final rejection, even if
1. A Notice of Appeal was filed on Appellant's 37 CFR 1.192(a), or any extension thereof (37 CFR	1.191(d)), to avoid dismissal of	riod set forth in the appeal.
2. The proposed amendment(s) will not be entered be	cause:	
(a) They raise new issues that would require further		ee NOTE below);
(b) They raise the issue of new matter (see Note be	•	
(c) ☐ they are not deemed to place the application in issues for appeal; and/or	better form for appeal by mater	ially reducing or simplifying the
(d) they present additional claims without cancelin NOTE:	g a corresponding number of fir	nally rejected claims.
3. Applicant's reply has overcome the following rejection	n(s):	
4. Newly proposed or amended claim(s) would b canceling the non-allowable claim(s).		
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for reapplication in condition for allowance because: See	econsideration has been consid Continuation Sheet.	ered but does NOT place the
6. The affidavit or exhibit will NOT be considered becauraised by the Examiner in the final rejection.	use it is not directed SOLELY to	issues which were newly
7. For purposes of Appeal, the proposed amendment(s explanation of how the new or amended claims wou) a) will not be entered or b) ld be rejected is provided below] will be entered and an or appended.
The status of the claim(s) is (or will be) as follows:		
Claim(s) allowed:		
Claim(s) objected to:		
Claim(s) rejected:		
Claim(s) withdrawn from consideration:		
8. \square The proposed drawing correction filed on is a)	approved or b) disappro	ved by the Examiner.
9. Note the attached Information Disclosure Statement(
0. Other:	/ · · · · · · · · · · · · · · · · · · ·	_
Patent and Trademark Office		

Continuation of 5. does NOT place the application in condition for allowance because: the teaching that the Examiner is relying on in both 103 rejections is that the prosthetic graft of Dumican and the suture anchor of Li, both have sutures or suture material attached thereto and the entire device is packaged and sterilized. Both Dumican and Li teach a pre-assembled device ready for use once the package is opened for surgery. McGuire does disclose each and every element of the package or kit, i.e. see col. 5, lines 66,67 which discloses a fixation device. However, what the Examiner is relying on in both secondary references is that all elements of these devices are packaged and sterilized.

Bruce Snow Primary Examiner